ArticleCureus2025
Oligocentric Castleman Disease (OligoCD): A Novel Diagnostic Entity in the Spectrum of Castleman Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease (CD) is a rare lymphoproliferative disorder traditionally classified as unicentric (UCD) or multicentric (MCD). However, some cases exhibit features that do not fit either category. These atypical cases warrant recognition as a distinct subtype, proposed here as oligocentric Castleman disease (OligoCD). A 38-year-old woman presented with bilateral lacrimal gland swelling and cervical lymphadenopathy, fatigue, and low-grade fever. Laboratory investigations, including hemogram, liver and kidney function tests, inflammatory markers, and interleukin-6 (IL-6), were within normal limits, except for mildly elevated erythrocyte sedimentation rate (ESR) and immunoglobulin G4 (IgG4) levels, elevated to approximately twice the upper limit of normal. Imaging did not reveal any other lymphadenopathy or systemic involvement. Lymph node biopsy revealed features of the hyaline-vascular variant of Castleman disease, confirmed on immunohistochemistry. The differential diagnosis of IgG4-related disease (RD) was considered but ruled out due to the non-fulfillment of the clinical diagnostic criteria and the absence of plasma cell infiltrate on histopathological examination. The presentation, however, did not fulfil the criteria for either UCD or MCD. She had an excellent response to prednisolone initially and a complete response to rituximab. This case underscores the need to broaden the existing diagnostic framework for Castleman disease. The clinical and histopathological findings favor recognizing oligocentric Castleman disease as a novel intermediate subtype within the disease spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.